Cargando…

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors

Paclitaxel is one of the most widely used chemotherapeutic agents thanks to its effectiveness and broad spectrum of antitumor activity. However, it has a very poor aqueous solubility and a limited specificity. To solve these handicaps, a novel paclitaxel-trastuzumab targeted transport nanosystem has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nieto, Celia, Centa, Ariana, Rodríguez-Rodríguez, Jesús A., Pandiella, Atanasio, Martín del Valle, Eva M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669497/ https://www.ncbi.nlm.nih.gov/pubmed/31261957 http://dx.doi.org/10.3390/nano9070948

Ejemplares similares

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
por: Díaz-Gil, Laura, et al.
Publicado: (2021)

The immunoglobulin‐like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation
por: Centa, Ariana, et al.
Publicado: (2018)

MZ1 co-operates with trastuzumab in HER2 positive breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018)

Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine
por: Nieto, Celia, et al.
Publicado: (2020)

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study
por: Ocana, Alberto, et al.
Publicado: (2017)

Nature-Inspired Nanoparticles as Paclitaxel Targeted Carrier for the Treatment of HER2-Positive Breast Cancer
por: Nieto, Celia, et al.
Publicado: (2021)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids
por: Rodríguez, Cristina E., et al.
Publicado: (2015)

Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2021)

Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy
por: Jung, Minkyu, et al.
Publicado: (2012)

HER3 in cancer: from the bench to the bedside
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2022)

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
por: Hurvitz, Sara A., et al.
Publicado: (2013)

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer
por: Gori, S, et al.
Publicado: (2004)

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
por: Patel, Tejal A., et al.
Publicado: (2019)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
por: Fiszman, Gabriel L., et al.
Publicado: (2011)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Inorganic Nanovehicle Targets Tumor in an Orthotopic Breast Cancer Model
por: Choi, Goeun, et al.
Publicado: (2014)

Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
por: Han, Hye-Suk, et al.
Publicado: (2009)

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
por: Esteva, Francisco J, et al.
Publicado: (2007)

Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies
por: Ocaña, Alberto, et al.
Publicado: (2016)

Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab
por: Sorscher, Steven
Publicado: (2013)

Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer
por: Nahta, Rita
Publicado: (2012)

Trastuzumab-targeted gene delivery to Her2-overexpressing breast cancer cells
por: Mann, K, et al.
Publicado: (2016)

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
por: Pegram, Mark D., et al.
Publicado: (2018)

Optimize the combination regimen of Trastuzumab and Nab-paclitaxel in HER2-positive tumors via modulating Caveolin-1 expression by lovastatin
por: Yang, Canyu, et al.
Publicado: (2022)

A supramolecular nanovehicle toward systematic, targeted cancer and tumor therapy
por: Liang, Ruizheng, et al.
Publicado: (2015)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Graphene-based nanovehicles for photodynamic medical therapy
por: Li, Yan, et al.
Publicado: (2015)

A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer
por: Bussolati, G, et al.
Publicado: (2005)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
por: Saavedra Santa Gadea, Omar, et al.
Publicado: (2017)

Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers
por: Wu, Yanyuan, et al.
Publicado: (2020)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
por: Xing, Fei, et al.
Publicado: (2023)

Ultrasonic Film Rehydration Synthesis of Mixed Polylactide Micelles for Enzyme-Resistant Drug Delivery Nanovehicles
por: Stepanova, Darya A., et al.
Publicado: (2022)

Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer
por: Niza, Enrique, et al.
Publicado: (2019)

Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2022)

BET inhibitors as novel therapeutic agents in breast cancer
por: Ocaña, Alberto, et al.
Publicado: (2017)

Neutrophil Camouflaged Stealth Nanovehicle for Photothermal‐Induced Tumor Immunotherapy by Triggering Pyroptosis
por: Yu, Xuya, et al.
Publicado: (2023)

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment
por: de Langen, Adrianus J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4ll0acj7stfk77p0njjpl3j3i1